Roginolisib demonstrates safety and achieves over 90% continuous PI3Kδ inhibition in patients with advanced cancers, including metastatic uveal melanoma, with median OS of 20.8 months.
- Open access
Ocular Oncology and Treatments
Moving in Frontiers in Genetics, Nature Communications and Nature Medicine.
- Moved, week to 23 Oct 2026
- 0
- Papers in 60 days
- 3
Add Ocular Oncology and Treatments as an interest in JClubFree on iPhone and Android · interests shape Home, Discover and your digest
Rebuilt
Moved this week
Nothing in this topic has moved yet this week.
Latest in Ocular Oncology and Treatments
Newest first · last 60 days
Eighteen candidate TCDD-associated targets, including five hub genes, were identified in retinoblastoma, with CDK1 showing the strongest link to cell-cycle dysregulation.
- Open access
DYP688, an antibody-drug conjugate targeting PMEL with a Gq/11 inhibitor payload, shows promising activity in GNAQ/GNA11-mutant melanomas with a 19.7% response rate.
- Open access
Add Ocular Oncology and Treatments as an interest in JClub
Browse JClub
Journals this month
- bioRxiv6183
- medRxiv1716
- PNAS472
- Sci Adv398
- JAMA274
- Environ Res230
- BMJ200
- Nat Commun171
- Environ Pollution165
- Nature161
- NEJM146
- Science141
- Lancet132
- Cell Rep130
- Curr Biol108
- J Exp Bot108
- mBio107
- Plant Cell Environ107
Topics moving, week to 23 Oct 2026
- Single-cell and spatial transcriptomics6
- Neuroinflammation and Neurodegeneration Mechanisms5
- Bacteriophages and microbial interactions5
- Gut microbiota and health5
- Genomics and Phylogenetic Studies4
- Cancer Genomics and Diagnostics4
- Cancer Immunotherapy and Biomarkers4
- Alzheimer's disease research and treatments3
- Inflammatory Bowel Disease3
- Influenza Virus Research Studies3